Purpose: To report the combination cocktail of strong steroid, non-steroidal anti-inflammatory drug (NSAID), and carbonic anhydrase inhibitor drops for treatment of cystoid macular edema.
Methods: This is a retrospective case series of patients with cystoid macular edema managed with a topical combination of strong steroid (difluprednate), NSAID, and carbonic anhydrase inhibitor drops. The patients were followed with optical coherence tomography and fluorescein angiography.
Results: In our six cases, resolution of the cystic edema with improvement in visual acuity was achieved with the use of a combination cocktail of drops. Leakage on fluorescein angiography and cystic edema on optical coherence tomography both responded to treatment with the topical cocktail of drops.
Conclusion: A topical cocktail of strong steroid, NSAID, and carbonic anhydrase inhibitor drops are effective for managing cystoid macular edema. Further studies comparing this combination with more invasive treatments should be undertaken to determine the efficacy of this cocktail over other treatment options.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671768 | PMC |
| http://dx.doi.org/10.2147/IMCRJ.S92794 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polmacoxib 2mg in patients with mild to moderate idiopathic osteoarthritis of hip/knee-a randomized, double-anonymous study.
Pain Manag
September 2024
Department of Clinical Development & Medical Affairs, Hetero Labs Limited, Hyderabad, India.
Aim: Polmacoxib, a new COX-2 inhibitor with carbonic anhydrase (CA) inhibitory action, is expected to help minimize the adverse effects associated with other NSAIDs, like GI (gastrointestinal) and CV (cardiovascular) system- related issues. The comparative efficacy and safety of polmacoxib 2 mg (manufactured by Hetero Labs Limited) versus celecoxib 200 mg (manufactured by Hetero Labs Limited) were assessed in this randomized, double-anonymous, clinical study in Indian adult patients diagnosed with idiopathic osteoarthritis (OA) of the.
Patients & Methodology: 18 years and older patients of either sex, clinically and radiographically diagnosed idiopathic knee or hip OA were randomized to receive either polmacoxib or celecoxib in a 1:1 ratio.
Polmacoxib: A Review of the Newer Non-steroidal Anti-inflammatory Drug in Osteoarthritis.
Cureus
April 2024
Established Pharmaceuticals Division, Abbott Healthcare Pvt. Ltd., Mumbai, IND.
Osteoarthritis represents a huge socioeconomic burden and has a significant impact on daily life and productivity. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the management of osteoarthritis to curb inflammation, pain, and stiffness and improve physical function. However, due to the various side effects, most healthcare professionals avoid using NSAIDs for a long period.
View Article and Find Full Text PDFScoping review of nonsurgical treatment options for macular holes.
Surv Ophthalmol
September 2024
Ophthalmology department, Royal Adelaide Hospital, Adelaide SA 5000, Australia; Machine Learning Division, Ophthalmic Research Laboratory, University of Adelaide, Adelaide SA 5005, Australia.
Article Synopsis
- - Macular holes (MH) are retinal defects that impact central vision, and while vitrectomy with inner limiting membrane (ILM) peel is the main treatment, non-surgical options are being explored to reduce surgical risks.
- - A literature review analyzed various non-surgical treatments for MH, including laser therapy, medications like NSAIDs and steroids, and intravitreal injections, identifying anatomical closure rates ranging from 36% to 84% depending on the treatment.
- - While non-surgical options show promise, especially for smaller MH, there's still limited evidence for routine use, and vitrectomy with ILM peel remains the most reliable method for treating full-thickness MH.
Inflammatory-stimuli-responsive turn-on NIR fluorogenic theranostic prodrug: adjuvant delivery of diclofenac and hydrogen sulfide attenuates acute inflammatory disorders.
J Mater Chem B
May 2024
Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati 781039, Assam, India.
Prolonged use of very commonly prescribed non-steroidal anti-inflammatory drugs (NSAIDs) is often associated with undesired side effects, including gastrointestinal ulcers due to the non-selective inhibition of cyclooxygenases. We describe the development of an inflammatory-stimuli-responsive turn-on fluorogenic theranostic prodrug DCF-HS for adjuvant drug delivery. Upon activation by reactive oxygen species (ROS), the prodrug releases diclofenac DCF (active drug) and the NIR fluorophore DCI-NH2 along with carbonyl sulfide (COS).
View Article and Find Full Text PDFDrug interactions of carbonic anhydrase inhibitors and activators.
Expert Opin Drug Metab Toxicol
March 2024
Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, FI, Italy.
Introduction: Carbonic anhydrases (CAs, EC 4.2.1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!